IRIS Accounts Production v23.3.1.45 14082387 Board of Directors 3.5.22 31.5.23 31.5.23 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh140823872022-05-02140823872023-05-31140823872022-05-032023-05-31140823872022-05-0214082387ns10:Originalns15:EnglandWales2022-05-032023-05-3114082387ns14:PoundSterlingns10:Original2022-05-032023-05-3114082387ns10:Originalns10:Director12022-05-032023-05-3114082387ns10:Original2022-05-032023-05-3114082387ns10:Original2023-05-3114082387ns10:Originalns10:PrivateLimitedCompanyLtd2022-05-032023-05-3114082387ns10:Originalns10:SmallEntities2022-05-032023-05-3114082387ns10:Originalns10:AuditExempt-NoAccountantsReport2022-05-032023-05-3114082387ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-05-032023-05-3114082387ns10:SmallCompaniesRegimeForAccountsns10:Original2022-05-032023-05-3114082387ns10:Originalns10:FullAccounts2022-05-032023-05-3114082387ns10:Originalns10:OrdinaryShareClass12022-05-032023-05-3114082387ns10:Originalns10:Director22022-05-032023-05-3114082387ns10:Originalns10:RegisteredOffice2022-05-032023-05-3114082387ns10:Originalns5:CurrentFinancialInstruments2023-05-3114082387ns5:ShareCapitalns10:Original2023-05-3114082387ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-05-3114082387ns10:Originalns5:PlantMachinery2022-05-032023-05-3114082387ns10:Originalns5:FurnitureFittings2022-05-032023-05-3114082387ns10:Originalns5:ComputerEquipment2022-05-032023-05-3114082387ns10:Originalns5:PlantMachinery2023-05-3114082387ns10:Originalns5:FurnitureFittings2023-05-3114082387ns10:Originalns5:ComputerEquipment2023-05-3114082387ns10:Originalns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-05-3114082387ns10:Originalns5:CurrentFinancialInstruments2022-05-032023-05-3114082387ns10:Originalns5:WithinOneYear2023-05-3114082387ns5:BetweenOneFiveYearsns10:Original2023-05-3114082387ns10:Originalns5:AllPeriods2023-05-3114082387ns10:Originalns10:OrdinaryShareClass12023-05-31
REGISTERED NUMBER: 14082387 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS

FOR THE PERIOD 3 MAY 2022 TO 31 MAY 2023

FOR

SUSSEX PATHOLOGY LIMITED

SUSSEX PATHOLOGY LIMITED (REGISTERED NUMBER: 14082387)






CONTENTS OF THE FINANCIAL STATEMENTS
for the period 3 May 2022 to 31 May 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


SUSSEX PATHOLOGY LIMITED

COMPANY INFORMATION
for the period 3 May 2022 to 31 May 2023







DIRECTORS: Y E Fadeev
Y V Fadeeva





REGISTERED OFFICE: 32A Chatsworth Road
Brighton
BN1 5DB





REGISTERED NUMBER: 14082387 (England and Wales)





ACCOUNTANTS: Plus Accounting
Chartered Accountants
Preston Park House
South Road
Brighton
East Sussex
BN1 6SB

SUSSEX PATHOLOGY LIMITED (REGISTERED NUMBER: 14082387)

BALANCE SHEET
31 May 2023

Notes £   
FIXED ASSETS
Tangible assets 4 128,643

CURRENT ASSETS
Stocks 20,000
Debtors 5 10,944
Cash at bank 87,631
118,575
CREDITORS
Amounts falling due within one year 6 (799,833 )
NET CURRENT LIABILITIES (681,258 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(552,615

)

CAPITAL AND RESERVES
Called up share capital 8 100
Retained earnings (552,715 )
SHAREHOLDERS' FUNDS (552,615 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 May 2023.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 May 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 1 February 2024 and were signed on its behalf by:





Y E Fadeev - Director


SUSSEX PATHOLOGY LIMITED (REGISTERED NUMBER: 14082387)

NOTES TO THE FINANCIAL STATEMENTS
for the period 3 May 2022 to 31 May 2023

1. STATUTORY INFORMATION

Sussex Pathology Limited is a private company, limited by shares, registered in England and Wales. The company's registered number, registered office address and business address can be found on the Company Information page.

The presentational currency of the financial statements is the Pound Sterling (£).

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Revenue is measured at the fair value of the consideration received or receivable net of VAT and trade discounts, and is recognised as follows:

Revenue from the sale of laboratory services is recognised at the point of sale.

Tangible fixed assets
Tangible fixed assets are stated at cost, or deemed cost, [or valuation] less accumulated depreciation and accumulated impairment losses. Cost includes costs directly attributable to making the asset capable of operating as intended by management.

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant & machinery-25% reducing balance
Fixtures & fittings-25% reducing balance
Computer equipment-3 years on cost

Stocks
Stocks, which consist of laboratory consumables, are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Financial instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


SUSSEX PATHOLOGY LIMITED (REGISTERED NUMBER: 14082387)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the period 3 May 2022 to 31 May 2023

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity. Once the contributions have been paid the Company has not further payment obligations.

The contributions are recognised as an expense in the Income Statement when they fall due. Amounts not paid are shown in accruals as a liability on the Balance Sheet. The assets of the plan are held separately from the Company in independently administered funds.

Impairment
At each balance sheet date, the company reviews the carrying amount of its assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss, if any. Where it is not possible to estimate the recoverable amount of an asset, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 5 .

SUSSEX PATHOLOGY LIMITED (REGISTERED NUMBER: 14082387)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the period 3 May 2022 to 31 May 2023

4. TANGIBLE FIXED ASSETS
Fixtures
Plant and and Computer
machinery fittings equipment Totals
£    £    £    £   
COST
Additions 133,638 26,083 12,791 172,512
At 31 May 2023 133,638 26,083 12,791 172,512
DEPRECIATION
Charge for period 34,368 6,708 2,793 43,869
At 31 May 2023 34,368 6,708 2,793 43,869
NET BOOK VALUE
At 31 May 2023 99,270 19,375 9,998 128,643

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Other debtors 10,944

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
£   
Other creditors 799,833

Other creditors includes loans of £705,981, interest of £6,041 was charged at a rate of 3% per annum.

7. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
£   
Within one year 23,150
Between one and five years 43,277
66,427

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal
value: £   
100 Ordinary £1 100

100 ordinary shares of £1 each were issued on incorporation.